A multicentre, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections

International Journal of Clinical Practice

Volumn 52, Issue 2, 1998, Pages 69-74

  Nicodemo, A C ^a   Robledo, J A ^b   Jasovich, A ^c   Neto, W ^d,e  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Unidad de Biología Celular y Molecular   (Colombia)

^c Instituto Dupuytren   (Argentina)

^d R W JOHNSON PHARMACEUTICAL RES I   (United States)

^e Robert Wood Johnson P   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; LEVOFLOXACIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL SKIN DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SOUTH AND CENTRAL AMERICA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; VOMITING;

EID: 0031935387     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Bisno AL. Cutaneous infections: microbiologic and epidemiologic considerations. Am J Med 1987; 76(suppl 5A): 172-179.
2. Sheagren JD. Treatment of skin and skin structure infection in the patient at risk. Am J Med 1984; 76(suppl 5A): 180-186.
3. Peréz-Ruvalcaba JA, Quintero-Pérez NP, Morales-Reyes JJ et al. Double-blind comparison of ciprofloxacin with cefotaxime in the treatment of skin and skin structure infections. Am J Med 1987; 82(suppl 4A): 242-246.
4. Self PL, Zeluff BA, Sollo D, Gentry LO. Use of ciprofloxacin in the treatment of serious skin and skin structure infections. Am J Med 1987; 82(suppl 4A): 239-241.
5. Parish LC, Asper R. Systemic treatment of cutaneous infections. Am J Med 1987; 82:(suppl 4A): 227-229.
6. Fujimoto T, Mitsuhashi S. In vitro antibacterial activity of DR-3355, the S-( - ) isomer of ofloxacin. Chemotherapy 1990; 36: 268-276.
7. Fu KP, Lafredo SC, Foleno B et al. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother 1992; 36: 860-866.
8. Une T, Fujimoto T, Sato K, Osada Y. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother 1988; 32: 1336-1340.
9. Chien SC, Rogge MC, Gisclon LG et al. Pharmacokinetic profile of levofloxacin following once daily 500 mg oral or intravenous doses. Antimicrob Agents Chemother 1997; 41: 2256-2260.
10. Bergan T, Thorsteinsson SB, Solberg R et al. Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. Am J Med 1987; 82(suppl 4A): 97-102.
11. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. M2-A3. Villanova, PA, 1983.
12. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Villanova, PA, 1988.
13. Blackwelder WC. Proving the null hypothesis in clinical trials. Controlled Clin Trials 1982; 3: 345-353.
14. Makuch R, Simon R. Sample size requirement for evaluating a conservative therapy. Cancer Treat Rep 1978; 62: 1037-1040.
15. Jick SS, Jick H, Dean AD. A follow-up safety study of ciprofloxacin users. Pharmacotherapy 1993; 13(5): 461-464.
16. Davis R, Markham A, Balfour JA. Ciprofloxacin: an updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 1996; 51(6): 1019-1074.
17. RW Johnson Pharmaceutical Research Institute, Raritan, NJ, USA. Data on file.
18. Nichols R, Smith J, Gentry LO et al. Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections. South Med J 1997; 90: 1193-1200.